PRESS RELEASE

Stockholm, Sweden, 31 August 2018



New number of shares and votes in Swedish Orphan Biovitrum AB (publ)

As per 31 August 2018, the total number of shares in Swedish Orphan Biovitrum AB (publ) (Sobi™) amounts to 273,322,117 shares. All shares are common shares. The total number of votes is 273,322,117. The increase in the number of shares and votes results from an issue of 814,409 class C shares. The class C shares have been issued for the purpose of ensuring fulfilment of commitments under incentive programmes and have by virtue of the conversion clause in the articles of association been converted to common shares. As per 31 August 2018 the company holds 3,665,197 common shares.

About Sobi™

Sobi™ is an international speciality healthcare company dedicated to rare diseases. Our vision is to be recognised as a global leader in providing access to innovative treatments that transform lives for individuals with rare diseases. The product portfolio is primarily focused on treatments in Haemophilia and Specialty Care. Partnering in the development and commercialisation of products in specialty care is a key element of our strategy. Sobi has pioneered in biotechnology with world-class capabilities in protein biochemistry and biologics manufacturing. In 2017, Sobi had total revenues of SEK 6.5 billion and approximately 850 employees. The share (STO:SOBI) is listed on Nasdaq Stockholm. More information is available at www.sobi.com.

For more information please contact

Media relations Linda Holmström, Senior Communications Manager +46 708 734 095 linda.holmstrom@sobi.com Investor relations
Jörgen Winroth, Vice President, Head of Investor Relations
+1 347 224 0819, +1 212 579 0506
jorgen.winroth@sobi.com

The above information has been made public in accordance with the Swedish Financial Instruments Trading Act. The information was released for public distribution on 31 August 2018 at 08:00 CET.